Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders

Multicenter Study To Evaluate The Efficacy Of Silymarin In Addition To Combination-Therapy With Pegylated Interferon Alfa 2a (Peg-Ifn Alfa 2a) And Ribavirin In Patients With Chronic Hepatitis C

By chance the investigators found that iv. silibinin has a potent antiviral effect against the hepatitis C virus. Based on the results of the dose finding study (published) te optima dosing schedule is explored.This study will be evaluate whether the highest active dose given for the optimal time combined with standard of care will result in a sustained virologic response (=cure of hepatitis C).

Since the publication of the first data the optimal dosing schedule is investigated

Inclusion Criteria:

• Nonresponders to full dose PEG-IFN/RBV therapy
• Liver biopsy within the last 2 year

Exclusion Criteria:

• Intolerance to one of the study drugs
• Coinfection with HIV/HBV